PURPOSE: To compare the correlation of the fellow-eye's intraocular pressure (IOP) response in one-eye trials performed separately for each eye with that of bilateral treatment in normal subjects. METHODS: A one-eye trial with topical latanoprost applied once daily for 7 days was carried out in the right eye and then in the left eye of 41 normal subjects. Bilateral treatment was performed in a different set of 41 normal subjects. IOPs were measured at 3 time points on day 0 and on day 7. RESULTS: Latanoprost significantly reduced IOP of treated eyes in one-eye trials (2.8+/-1.6 and 2.7+/-1.6 mm Hg in the first and second trial, respectively) and in bilateral treatments (2.8+/-1.3 and 2.6+/-1.4 mm Hg in the right and left eye, respectively). Correlation of mean diurnal IOP reduction between 2 one-eye trials was poor (r2=0.102), even after subtracting the nontreated eye IOP fluctuations from the treated eye IOPs (r2=0.097), but that between fellow eyes in bilateral treatment was excellent (r=0.849). Correlation of baseline IOP at each time point between fellow eyes in one-eye trials and bilateral treatment (r2=0.729 to 0.949) was better than that in the same eye between 2 one-eye trials (r2=0.319 to 0.631). CONCLUSIONS: Fellow eyes in normal subjects showed a symmetrical IOP response to short-term bilateral treatment with latanoprost, although they did not respond symmetrically to one-eye trials performed separately for each eye. Poor correlation of IOP changes between 2 one-eye trials may be caused by different IOP responsiveness to latanoprost at each trial, rather than asymmetrical IOP fluctuations.
PURPOSE: To compare the correlation of the fellow-eye's intraocular pressure (IOP) response in one-eye trials performed separately for each eye with that of bilateral treatment in normal subjects. METHODS: A one-eye trial with topical latanoprost applied once daily for 7 days was carried out in the right eye and then in the left eye of 41 normal subjects. Bilateral treatment was performed in a different set of 41 normal subjects. IOPs were measured at 3 time points on day 0 and on day 7. RESULTS:Latanoprost significantly reduced IOP of treated eyes in one-eye trials (2.8+/-1.6 and 2.7+/-1.6 mm Hg in the first and second trial, respectively) and in bilateral treatments (2.8+/-1.3 and 2.6+/-1.4 mm Hg in the right and left eye, respectively). Correlation of mean diurnal IOP reduction between 2 one-eye trials was poor (r2=0.102), even after subtracting the nontreated eye IOP fluctuations from the treated eye IOPs (r2=0.097), but that between fellow eyes in bilateral treatment was excellent (r=0.849). Correlation of baseline IOP at each time point between fellow eyes in one-eye trials and bilateral treatment (r2=0.729 to 0.949) was better than that in the same eye between 2 one-eye trials (r2=0.319 to 0.631). CONCLUSIONS: Fellow eyes in normal subjects showed a symmetrical IOP response to short-term bilateral treatment with latanoprost, although they did not respond symmetrically to one-eye trials performed separately for each eye. Poor correlation of IOP changes between 2 one-eye trials may be caused by different IOP responsiveness to latanoprost at each trial, rather than asymmetrical IOP fluctuations.
Authors: Anjali M Bhorade; Bradley S Wilson; Mae O Gordon; Paul Palmberg; Robert N Weinreb; Eydie Miller; Robert T Chang; Michael A Kass Journal: Ophthalmology Date: 2010-08-12 Impact factor: 12.079